Cosmetic Surgery Today, the popular online resource for unbiased, comprehensive information on all major and minor cosmetic surgical procedures, issued a report today on Lumixyl: A Safer Option to Hyperpigmentation Treatment.
The report notes the following;
“Commonly occurring among middle-aged women, hyperpigmentation is usually a harmless condition wherein the skin is darkened in patches different from that of the surrounding skin. This condition is the result of an overproduction and the formation of skin deposits of melanin, the dark pigment responsible for the skin’s normal color.
Hyperpigmentation either occurs as focal, or as diffuse. Focal hyperpigmentation usually occurs after injury and other causes of inflammation. Diffuse hyperpigmentation, also known as melanism or melanosis, comes as a result of a drug reaction, or if you are suffering from Addison’s disease.
Treatment of Hyperpigmentation: Lumixyl vs. Hydroquinone
Ways of evening skin tone to treat hyperpigmentation have been steadily developed by experts. Some of these procedures are skin brightening techniques that make use of topical treatments such as lumixyl and skin brightening creams that contain hydroquinone.
Hydroquinone is a skin-bleaching agent that inhibits the tyrosinase enzyme to prevent the transformation of dopamine to melanin. Treatment of hyperpigmentation would take up to six months before showing any results. It has been the most common hyperpigmentation topical treatment, until the FDA proposed to ban hydroquinone in 29 August 2006 as a reaction to compelling tests that show hydroquinone’s propensity to act as a carcinogen, a cancer-causing chemical, when tested on rats.
Hydroquinone has also been hypothesized to have been the cause of ochronosis, a medical condition wherein the skin becomes dark and thick, and the appearance of yellow, dome-shaped spots in the skin of black men and women.
Recent developments introduced Lumixyl, a topical skin brightening and moisturizing cream that is milder compared to hydroquinone. Developed by dermatological researchers at Stanford University, it uses peptide technology to combat mild to moderate hyperpigmentation such as sun spots, age spots, uneven skin tone, and post-inflammatory hyperpigmentation.
Known for its non-toxic properties, it uses synthetic peptide, a substance that consists of a sequence of amino acids, aided by a couple of ingredients known to have been good treatment options for hyperpigmentation. It works by slowing down the overproduction of melanin, and avoids causing irritation, unlike other skin brightening products. It does not bleach the skin unlike hydroquinone.”
The report goes on to discuss the studies that back the Lumixyl peptide technology and possible benefits from using Lumixyl to treat Atopic Dermatitis. To see the entire article from Cosmetic Surgery Today, click the link HERE
Originally launched as a single Topical Brightening Creme, the Lumixyl Peptide technology has more recently been formulated into a comprehensive skin care system designed to 1) reduce the overproduction of melanin in skin, 2) stimulate cellular turnover, 3) exfoliate and peel away older skin, and 4) protect skin from damaging UV rays that may otherwise stimulate the formation of new hyperpigmentation in the future. Together, the products in this system work synergistically to accomplish something that no single product can, and to brighten skin without the side-effects commonly associated with products that contain harsh ingredients like hydroquinone.
This breakthrough system is the first real alternative to hydroquinone to come along in decades, and is rapidly being embraced by dermatologists, plastic surgeons and their patients throughout the United States and many other countries around the world.
More information on the Lumixyl Topical Brightening System and the exciting new Lumixyl SilkPeel procedure can be found HERE at the ENVY Medical website. To find a Lumixyl physician near you, click HERE.
About Lumixyl. Lumixyl is manufactured and marketed by Envy Medical, Inc. Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion™ for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available in a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com or by calling (888) 848-3633.
For media inquiries or to secure expert testimonial please contact Melissa Kelz, Principal, Melissa Kelz PR at firstname.lastname@example.org (312) 543-8300